Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data comparing them in the same cohort. We compared the prognostic performance of the EndoPredict (EP) test (standardized for pathology laboratory) with the research-based PAM50 non-standardized qRT-PCR a...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Miguel, Brase, Jan C., Ruiz, Amparo, Prat, Aleix, Kronenwett, Ralf, Calvo, Lourdes, Petry, Christoph, Bernard, Philip S., Ruiz-Borrego, Manuel, Weber, Karsten E., Rodriguez, César A., Alvarez, Isabel M., Segui, Miguel A., Perou, Charles M., Casas, Maribel, Carrasco, Eva, Caballero, Rosalía, Rodriguez-Lescure, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788691/
https://www.ncbi.nlm.nih.gov/pubmed/26909792
http://dx.doi.org/10.1007/s10549-016-3725-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788691/
https://www.ncbi.nlm.nih.gov/pubmed/26909792
http://dx.doi.org/10.1007/s10549-016-3725-z

Ejemplares similares